4Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet, 1992, 340: 1111-1115.
5Anderson TJ,Meredith IT,Yeung AC,et al.The effect of cholesterol-lowering and antioxidant therapy on endothelium- dependent coronary vasomotion.N Engl J Med,1995,332:488-493.
6Jarvisalo MJ,Toikka JO,Vasankari T,et al. HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease. Atherosclerosis, 1999,147:237-242.
7Schwartz GG,Olsson AG,Ezekowitz MD,et al.MIRACL Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes :the MIRACL study: a randomized controlled trial. JAMA,2001,285:1711-1718.
8Arntz HR, Agrawal R, Wunderlich W,et al. Beneficial effects of pravastatin(+/-cholestiramine/ niacin)initiated immediately after a coronary event(the randomized Lipid-coronary artery disease[L-CAD]study).Am J Cardiol,2000,86:1293-1298.
9Nissen SE, Tuzcu EM,Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA,2004, 291:1071-1080.
10Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med, 2004, 350:1495-1504.
